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Coronavirus disease 2019 (COVID-19): 
a brief overview of features and current treatment
Abstract
Since the report of the first cases of pneumonia caused by SARS-CoV-2 in December 2019, COVID-19 has become a pandemic 
and is globally overwhelming healthcare systems. The symptoms of COVID-19 vary from asymptomatic infection to severe com-
plicated pneumonia with acute respiratory distress syndrome (ARDS) and multiple organ failure leading to death. The estimated 
case-fatality rate among infected patients in Wuhan, the city where the first case appeared, was 1.4%, with 5.1 times increase in 
the death rate among those aged above 59 years than those aged 30–59 years. In the absence of a proven effective and licensed 
treatment, many agents that showed activity against previous coronavirus outbreaks such as SARS and MERS have been used to 
treat SARS-CoV-2 infection. The SARS-CoV-2 is reported to be 80% homologous with SARS-CoV, and some enzymes are almost 
90% homologous. Antiviral drugs are urgently required to reduce case fatality-rate and hospitalizations to relieve the burden on 
healthcare systems worldwide. Randomized controlled trials are ongoing to assess the efficacy and safety of several treatment 
regimens.
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Introduction
Coronavirus disease 2019 (COVID-19) is 
caused by a novel coronavirus (2019-nCoV) 
that first manifested as atypical pneumonia and 
was distinct from usual pneumonia in terms of 
symptoms and lethality. On February 11, 2020, 
2019-nCoV was named severe acute respirato-
ry syndrome coronavirus 2 (SARS-CoV-2) by 
the International Committee on Taxonomy of 
Viruses. SARS-CoV-2 is a part of a large family 
of RNA viruses called Coronaviridae, which 
has four types: Alpha, Beta, Delta, and Gamma. 
Coronaviruses are known to infect humans and 
animals, including mammals and birds. Seven 
coronaviruses, commonly Betacoronavirus HCoV-
OC43 and HCoV-HKU1, and HCoV-229E and 
HCoV-NL63 from Alphacoronavirus genus have 
been known to cause human infections [1]. Infec-
tions caused by these viruses are often mild or 
asymptomatic. However, severe lower respiratory 
tract infections have been reported, especially 
among patients with chronic diseases, immune 
system dysfunction, and at extreme ages [1, 2].
Zoonotic coronaviruses have caused out-
breaks in humans, namely SARS-CoV (2003, in 
China) and MERS-CoV (2012, in Saudi Arabia). In 
late 2019, COVID-19 was first reported in Wuhan 
City, Hubei Province, China, when a group of hos-
pitalized patients with pneumonia of unknown 
etiology started to be seen [3]. SARS-CoV-2 shares 
viral structure and genetic sequence with both 
SARS-CoV and MERS-CoV of 70% and 40%, 
respectively [4]. This new disease was declared 
as a global pandemic by the World Health Orga-
nization (WHO) on March 11, 2020. 
Address for correspondence: Montaha Al-Iede, Department of Pediatrics, Jordan University Hospital, Amman, Jordan; e-mail: montaha95@yahoo.com
DOI: 10.5603/ARM.a2021.0041  |  Received: 17.10.2020  |  Copyright © 2021 PTChP  |  ISSN 2451–4934  |  e-ISSN 2543–6031
This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as 
long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
Montaha Al-Iede et al., Coronavirus disease 2019: features and treatment
159www.journals.viamedica.pl
Compared to adults, the number of reported 
pediatric cases infected with the novel corona-
virus (COVID-19) was significantly smaller [5]. 
Although the figure has been increasing every 
day, the data on children’s disease clinical char-
acteristics are still lacking. According to the 
clinical severity classification proposed by the 
COVID-19 guidelines in China, pediatric pa-
tients were more likely to have a milder clinical 
presentation, milder imaging findings, and less 
severe disease progression [6]. In adults, approx-
imately 5% of patients will require intensive 
care. Information on pediatric patients needing 
intensive care is very limited. However, infants 
under 1 year appear to have an increased risk of 
severe disease. The infant group had the highest 
proportion of clinically diagnosed disease, and 
there remains the possibility that other viruses 
such as influenza A/B and respiratory syncytial 
virus may have caused the increased severity of 
the disease [7].
The pediatric multisystem inflammatory syn-
drome has been associated with COVID-19; this 
rare syndrome shares common features with other 
pediatric inflammatory conditions, including: 
Kawasaki disease, staphylococcal and streptococ-
cal toxic shock syndromes, bacterial sepsis, and 
macrophage activation syndromes. It was initially 
described in Britain but has been reported from 
the US with increasing frequency. It can also 
present with unusual abdominal symptoms with 
excessive inflammatory markers. The case defini-
tion has been proposed as the following: I. A child 
presenting with persistent fever, inflammation 
(neutrophilia, elevated CRP and lymphopenia) 
and evidence of single or multi-organ dysfunction 
(shock, cardiac, respiratory, renal, gastrointestinal 
or neurological disorder) with additional fea-
tures. This may include children fulfilling full or 
partial criteria for Kawasaki disease. II. Exclusion 
of any other microbial cause, including bacterial 
sepsis, staphylococcal or streptococcal shock syn-
dromes, infections associated with myocarditis 
such as enterovirus. III. SARS-CoV-2 PCR testing 
may be positive or negative [8].
Structure and pathogenesis
SARS-CoV-2 virus has spike glycoproteins 
(S proteins) called peplomers. S protein is the 
receptor binding site and plays an important role 
in binding to receptors on the surface of host 
cells and mediating virus envelope-cell mem-
brane fusion [9]. The S protein has two subunits, 
S1 and S2, and both are necessary to help the 
virus invading host cells. SARS-CoV-2 binds to 
angiotensin-converting enzyme 2 (ACE2) recep-
tors on the targeted cells through its structural 
spike (S) glycoproteins S1 subunit. The virus uses 
a transmembrane serine protease 2 (TMPRSS2) 
for S protein priming as TMPRSS2 activates the 
spike and helps cleavage of ACE2. 
 TMPRSS2 acts on S2 subunit of S protein to 
facilitate the virus fusion to the cell membrane 
[10]. Once inside the host cells, the virus starts 
synthesizing RNA using its RNA-dependent 
RNA polymerase and viral structural proteins to 
complete virus formation and then virus release 
(Figure 1) [11].
The pathogenesis of the COVID-19 severity 
has not been understood yet. However, high levels 
of serum inflammatory cytokines such as inter-
feron-gamma (IFNγ), interferon gamma inducible 
protein (IP10), IL-12, IL-6 and IL-1 were noted 
activating the Th1 cell response [12]. Patients 
who were critically ill, requiring an intensive care 
unit (ICU) had higher levels of tumor necrosis 
factor-alpha (TNFα), monocyte chemo-attrac-
tant protein (MCP1), macrophage inflammatory 
protein (MIP1A) and IP10 than patients who did 
not require ICU, which supports the relationship 
between cytokines storm and disease severity 
[12]. Xu et al. [13] have reported the result of 
first pathologic autopsy of a COVID-19 patient 
that showed a diffuse alveolar injury and hyaline 
membrane formation supporting ARDS diagno-
sis. In addition, the pathological changes seen 
were similar to MERS and SARS [13]. Flow cytom-
etry revealed a significant reduction in CD4+ and 
CD8+ T lymphocytes counts in peripheral blood, 
which affects the immune defense mechanism. 
However, these T lymphocytes are in an overac-
tive condition as manifested by high Th17 counts 
and an increased cytotoxicity of CD8+ T lym-
phocytes leading to a significant immune tissue 
injury in the patient’s lungs and perhaps to the 
multisystem dysfunction [14]. This has provided 
a clue for COVID-19 treatmentby using agents 
directed against Th17 activity (Th17 inhibitors), 
however, this needs more research to further 
investigate Th1 and Th2 response in patients 
with COVID-19 to better understand the disease 
pathogenesis. 
Epidemiology and clinical presentation
Since the initial SARS-CoV-2 virus detection, 
more than 68 million cases of COVID-19 have 
been confirmed worldwide, with the majority of 
cases reported in the United States [15]. Accord-
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ing to a report that was published by the Chinese 
center for disease control and prevention on Feb-
ruary 11, 2020, among a total of 72,314 recorded 
cases, 62% were diagnosed based on a positive 
nasal swab for viral nucleic acid test, 22% were 
diagnosed based on their symptoms and history 
of exposures with no test performed because of 
insufficient capacity to test all suspected cases 
in China during the pandemic [16]. The major-
ity of cases (87%) were aged 30–79 years, 3% 
— 80 years or older, and only 2% were younger 
than 19 years [16]. In terms of disease severity, 
the majority of cases (81%) were labelled as mild 
cases that included patients with no pneumonia 
or mild pneumonia. Around 14% of the cases who 
had symptoms that suggest significant respira-
tory compromise such as difficulty of breathing, 
tachypnea (respiratory rate > 30/min), hypoxemia 
with a saturation of blood oxygen less than 93%, 
with or without the presence of lung infiltrates 
on chest x-ray were considered as severe. And 
5% of the total recorded cases were diagnosed 
to have a critical illness due to the presence of 
respiratory failure, hemodynamic instability, 
with/without multiple organ failure [16]. A possi-
ble explanation for the significant deterioration in 
the patients who become critically ill is thought 
to be due to a cytokine storm, which is a situation 
where there is an overproduction of cytokines that 
consequently leads to mutli-organ dysfunction 
and failure resulting in death [17]. 
Patients with COVID-19 typically have flu-
like symptoms such as a fever and a dry cough. 
However, old patients and those with chronic 
Figure 1. SARS-CoV’s life cycle within the host cells. SARS-CoV-2 binds to host ACE2 via spike protein(s). Then cleavage of S protein is facilitated 
by host transmembrane protease TMPRSS to activate membrane fusion. A released viral genome is translated into nonstructural polyproteins which 
are processed by viral proteases to create the replicase. This replicase is used to produce several copies of strands and subgenomic mRNAs that are 
translated by ribosomes into structural proteins. The negative-strand RNA is packaged by structural protiens, followed by budding into endoplasmic 
reticulum-Golgi intermediate compartmetn’s lumen. Finally, the viron is released as an exocytic vesicle 10 [11, with permission]
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medical conditions and comorbidities may pres-
ent with symptoms that suggest lower respiratory 
tract infection (pneumonia) such as chest pain, 
chest tightness and shortness of breath. Huang 
et al. [18] first reported symptoms related to 
COVID-19 among 41 hospitalized patients; fever 
(98%), cough (76%) and myalgia (44%) were the 
most common three symptoms observed. Other 
symptoms such as headache, sputum production, 
hemoptysis and diarrhea were less frequent [18]. 
However, some patients predominantly presented 
with sneezing, rhinorrhea and sore throat. More 
than half of the infected patients developed dys-
pnea [18]. Chen et al. [19] reported 99 patients 
with a confirmed SARS-CoV-2 infection diagnosed 
by rRT-PCR. Most subjects had fever and cough, 
(82%) and (81%), respectively. Other reported 
symptoms were difficulty of breathing, headache, 
chest pain and diarrhea. Furthermore, Wang et 
al. [20] noted symptoms among 138 hospitalized 
patients with confirmed COVID-19 — fever was 
the main symptom (98.6%), followed by fatigue 
(69.6%) and then dry cough (59.4%). Despite be-
ing the most commonly reported symptom, fever 
can be absent in early stages of the illness. A re-
cently published systematic review showed that 
36% of 3,470 confirmed cases of COVID-19 had 
no fever at the onset of symptoms [14]. 
Mao et al. reported neurological manifes-
tations of COVID-19 among 214 hospitalized 
patients, with hypogeusia and hyposmia in 5.6% 
and 5.1% of the subjects, respectively [21]. The 
clinical course of COVID-19 disease displays 
a wide spectrum of progression patterns. Look-
ing at the timeline of the infected cases from the 
onset of the disease, a median time of 8 days was 
noticed to develop dyspnea, 9 days to develop 
ARDS and 10.5 days to require mechanical ven-
tilation [12]. Severely ill patients with ARDS may 
quickly progress to multiple organ failure leading 
to death [22]. Lymphopenia is one of the clinical 
features of COVID-19 infection, which indicates 
an immunity suppression that may result in 
severe complications due to secondary bacterial 
and fungal infections. Huang et al. [18] in their 
screening study of 41 patients with COVID-19, 
observed that 26 (63%) of them had lymphopenia 
and 13 (32%) patients required ICU. The subjects 
admitted to ICU had higher plasma levels of 
interleukins (ILs-2, 7 and 10), granulocytes-mac-
rophage colony-stimulating factor (GM-CSF) and 
tumor necrosis factor alpha (TNF-α). 
The rise in inflammatory markers is the key 
point underlying the multisystem inflammatory 
response in COVID-19 [23]. The main inflam-
matory and immune markers correlating with 
COVID-19 disease include CRP, ESR, serum fer-
ritin, IL-6, IL-8, IL-10, and low count of lympho-
cytes, T cell, B cell and NK cell [23]. 
Transmission of SARS-2
Based on what has been reported about 
previous outbreaks caused by SARS and MERS, 
droplets are considered the main mode of trans-
mission. Close contact with an infected person 
can also transmit the infection. In addition, 
airborne transmission has been suggested espe-
cially when invasive respiratory procedures are 
performed such as endotracheal intubation [24]. 
The gastrointestinal symptoms that have been 
reported with infected patients are related to 
invade ACE2- expressing absorptive enterocytes 
from the ileum and colon, which suggests that 
the digestive system is a potential route for SARS- 
-CoV-2 infection [25].
Diagnostic testing
Detection of viral RNA by RT-PCR
This test is the most commonly used and con-
sidered more reliable [26]. It is performed using 
nasopharyngeal swabs or other upper respiratory 
tract specimens, including throat swab or even 
saliva. Viral RNA in the nasopharyngeal swab is 
measured by the cycle threshold (Ct). The Ct is the 
number of replication cycles needed to produce 
a fluorescent signal, with lower Ct values repre-
senting higher viral RNA loads. The Ct becomes 
detectable as early as on day 1 of symptoms and 
peaks within the first week of the symptom onset. 
This positivity starts to decline by week 3 and 
subsequently becomes undetectable. In severe 
cases, however, PCR positivity may persist be-
yond 3 weeks after the illness onset when most 
mild cases will yield a negative result [27]. In 
a study of 9 patients, it was noted that attempts 
to isolate the virus in culture were not successful 
beyond day 8 of the illness onset, which cor-
relates with the decline of infectivity beyond the 
first week even if the PCR remains positive, thus 
a “positive” PCR result reflects only the detection 
of viral RNA and does not necessarily indicate 
the presence of viable virus [28]. The timeline 
of PCR positivity is different in specimens other 
than nasopharyngeal swab with PCR positivity 
declining more slowly in sputum and stool than 
in nasopharyngeal specimens [28]. Wang and 
colleagues published a study to compare RT-PCR 
positivity in different types of clinical specimens 
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in 205 patients with confirmed COVID-19 infec-
tion — it was highest in bronchoalveolar lavage 
specimens (93%), followed by sputum (72%), 
nasal swab (63%), and pharyngeal swab (32%) 
[29]. Specificity of most of the RT-PCR tests is 
100% because the primer design is specific to 
the genome sequence of SARS-CoV-2. Occasional 
false-positive results may occur due to technical 
errors and reagent contamination.
Detection of antibodies to SARS-CoV-2
COVID-19 infection can also be proven indi-
rectly by measuring the host immune response 
to SARS-CoV-2 infection. Serological diagnosis 
is especially important for patients with mild to 
moderate illness who may present beyond the first 
2 weeks of the illness onset. Serological diagnosis 
is also becoming an important tool to understand 
the extent of COVID-19 in the community and 
to identify individuals who are immune and 
potentially “protected” from becoming infected. 
The most sensitive and earliest serological marker 
is the total of antibodies (IgM and IgG ELISA), 
which begin to increase from the second week 
of the symptom onset [30]. These antibodies can 
be found as early as on the fourth day after the 
symptom onset but higher levels occur in the 
second and third week of illness. Antibodies may 
have cross-reactivity with SARS-CoV and possi-
bly other coronaviruses. Rapid point-of-care tests 
for detection of antibodies have been widely de-
veloped and marketed and are of variable quality. 
They are considered qualitative in nature and can 
only indicate the presence or absence of SARS-
CoV-2 antibodies but don’t confirm the presence 
of neutralizing antibodies which can only be con-
firmed by a plaque reduction neutralization test. 
However, high titers of IgG antibodies detected 
by ELISA have been shown to positively correlate 
with neutralizing antibodies [31]. The long-term 
persistence and duration of protection conferred 
by the neutralizing antibodies remains unknown.
Radiological changes of COVID-19 pneumonia
Chest X-ray and CT scan are used for early 
detection of COVID-19 pneumonia. Chen et al. 
[18] reported bilateral pneumonia among 75% of 
their cohort (99 patients with COVID-19) based 
on chest X-ray and chest CT scan. A quarter of pa-
tients were diagnosed with unilateral pneumonia 
and only 14% showed a ground-glass appearance 
on their images. In addition to rRT-PCR, the use 
of chest imaging as a diagnostic and management 
tool of COVID-19 is still debatable as chest X-ray 
in adults has been found to be insensitive in 
mild or early COVID-19 infection [32]. Similarly, 
reported cases of children with COVID-19 showed 
completely normal X-ray on admission [33, 34]; 
however, in severe and more advanced cases, 
chest X-ray images were abnormal with bilateral 
multiple consolidation [35]. Jiehao et al. [36] re-
ported multiple patch-like shadows on chest X-ray 
images of 4 (40%) out of 10 infected children. 
Compared to X-ray, a CT scan was shown to 
be more sensitive in detecting early changes and 
progression of the disease [37]. In fact, abnormal 
CT scans have been used to diagnose COVID-19 in 
suspected cases who initially tested negative on 
RT-PCR but eventually had positive tests on re-
peated testing [38, 39].
The main radiological changes seen on 
chest CT scans of infected patients were bilat-
eral ground-glass opacities [12]. In children, 
the typical CT findings were unilateral or bi-
lateral subpleural groundglass opacities as well 
[33, 40–46]. Other studies have reported find-
ings of consolidations with and without air 
bronchogram and pleural effusion [35, 44, 45]. 
Furthermore, consolidations with surrounding 
halo sign were noticed in 50% of cases in a study 
conducted in children by Xia et al. [43]. More-
over, findings such as peribronchial distribution 
and bronchial thickening were more commonly 
seen in pediatric patients compared to the adult 
population [47].
In addition to its role in diagnosis, a high-res-
olution CT scan (HRCT) was shown by Liu et al. 
[48] to be useful as a potential screening tool as 
they used it to screen for COVID-19 in five pe-
diatric suspected cases, and it showed multiple 
ground-glass opacities. However, currently, the 
society of Thoracic Radiology and the American 
College of Radiology do not support the use of 
chest CT for routine screening of COVID-19 [49]. 
However, Ji et. al. [50] reported two pediatric cas-
es whose CT scans were completely normal [50]. 
Ultrasound (US) has an essential role in dif-
ferential diagnosis assessment and follow-up of 
hospitalized patients with COVID-19, especially 
in intensive care units, where access to CT scan 
is difficult [51]. However, ultrasound should not 
be used to replace CT scan [52]. Lung ultrasound 
can be applied to evaluate many pulmonary con-
ditions such as pleural effusion, atelectasis, con-
solidations, pleural effusions and pneumothorax. 
In COVID-19 patients, US allows evaluating the 
parenchyma inflammation progression, pleural 
thickening, and subpleural consolidations with 
or without air bronchograms [52].
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Case fatality
Estimating the lethality of COVID-19 dis-
ease is challenging [53]. The case-fatality ratio 
is used to assess the severity of a disease and 
effectiveness of a treatment [54]. To calculate 
the CFR, the number of known deaths over 
a certain period of time is divided by the num-
ber of confirmed cases (including deaths and 
recovered cases) during that time [54]. The CFR 
does differ from mortality rate which is another 
measure of death that reflects the portion of 
a population who dies during a certain period of 
time. To get an accurate CFR, the true number of 
infected patients is needed. This means that the 
CFR can be overestimated if the true number of 
infected persons is underestimated. Especially, 
if asymptomatic and mildly symptomatic infect-
ed patients do not present to hospitals. Moreover, 
CFRs can differ between different geographical 
areas, a reason being different medical services 
and facilities during the pandemic period [53], 
the use of inappropriate statistical methods and 
techniques [54], in addition to the sensitivity 
and specificity of serologic testing that is used 
to confirm infection [54].
Wu et al. [55] reported a total of 72,314 in-
fected cases with COVID-19 recorded by the Chi-
nese center for disease control and prevention, 
the overall CFR till February 24, 2020 and among 
the confirmed 44,672 cases, was 2.3%. There 
were no deaths recorded in children aged 9 years 
or younger. However, the CFR was up to 8% 
among the group of patients aged 70–79 years 
and even higher (14.8%) in the group of older 
patients (≥ 80 years). The CFR was the highest 
in the group of patients with critical illness 
(49%) [55]. In a recently published systematic 
review, the overall CFR was 3.7% (3,015 died of 
80,565 patients) [14]. 
Treatment
Repurposed drugs to treat SARS-CoV-2
Currently, there has been no potential therapy 
shown from randomized clinical trials to improve 
outcomes or to significantly reduce case-fatality 
rate among either suspected or confirmed cases 
of COVID-19. However, the researchers have 
used drugs targeted at the virus lifecycle steps, 
viral entry and immunity regulation pathways to 
provide drug therapy for COVID-19 [56]. Because 
of the critical need for effective therapies, there 
has been a clear interest in repurposing available 
agents for immediate use.
Various drugs that were active against SARS-
CoV and MERS-CoV have been considered as 
potential therapy to treat COVID-19. 
Chloroquine and hydroxychloroquine
Chloroquines have been used as antimalarial 
agents for decades [57]. Because of their im-
mune-modulatory properties, these agents have 
been considered to treat autoimmune diseases 
such as rheumatoid arthritis [57]. Chloroquine 
(CQ) and hydroxychlorquine (HCQ) have a po-
tential antiviral activity against SARS-CoV-2 by 
blocking several steps required for viral entry 
to host cells, including host cell receptor ter-
minal glycosylation, proteolytic processing and 
edosomal acidification [58], in adition to their 
immune-modulatory properties through inhibi-
tion of cytokine production and host cells lyso-
somal activity [59], both CQ and HCQ affect the 
viral entrance to the host cell through inhibiting 
ACE2 receptor binding to viral S protein by im-
pairment of terminal glycosylation of ACE2 on 
host cells, and inhibiting membrane fusion and 
uncoating [59]. Once inside the cell, CQ and HCQ 
concentrate inside the acidic organelles, such as 
lysosomes, endosomes and Golgi apparatus. Thus, 
using either CQ or HCQ therapy elevates the PH 
of the organelle that virus uses to replicate, which 
may negatively influence the viral entrance [60]. 
Lysosomal proteases play a role in fusion pro-
cess between the viral membrane and the host, 
alkalinization of lysosomes will negatively affect 
proteases activity causing impairment of fusion 
process [60]. Preventing virus-host fusion helps 
blocking the infection. Vincent et al. studied 
the efficacy of CQ on SARS-CoV infection and 
observed inhibition of SARS-CoV spread in cells 
treated with CQ prior and after the infection 
[60]. Thus, they suggested its prophylactic and 
therapeutic role.
Moreover, Gautret et al. reported a 70% viral 
clearance among 20 infected patients who were 
treated with HCQ at the sixth day of therapy. 
The authors also reported an increase in the viral 
clearance up to 100% after adding azithromycin 
to HCQ in 6 patients, which supports using this 
regimen to reduce the length of hospital stay 
[61]. However, the small size of the patients 
used azithromycin in this study (6 subjects), 
and were observed only for a short time (6 days), 
and taking into consideration the additive risk 
of developing cardiac complications, mainly QT 
prolongation with the combined therapy [61], 
they have encouraged to perform randomized 
controlled trials to assess this regimen’s efficacy. 
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In addition, surviving sepsis campaign guidelines 
on the management of critically ill adults with 
COVID-19 that have been published recently, pro-
vided no evidence to support this combination of 
therapy use in treatment of critically ill patients 
admitted to ICU [62]. This could be, though, due 
to multiple organ failure that critically ill patients 
have, which can influence the metabolism of 
these agents, and can potentially increase the risk 
of side effects. Whether to continue using QCs or 
to stop, RCTs are required. The solidarity and the 
discovery study are multicenter studies ongoing 
to provide a better understanding of antimalarial 
and other antiviral agents’ effects.
Safety and side effects
Both CQ and HCQ are distributed well 
throughout body systems after oral adminis-
tration and are cheap. The main side effects of 
these agents include diarrhea and vomiting [59]. 
Other serious side effects have been reported 
following a chronic use such as retinopathy and 
cardiomyopathy [63]. Moreover, toxicity due to 
CQ therapy has been seen in patients treated 
with high doses exceeding the therapeutic dosage 
limits. In contrary, HCQ is associated with fewer 
side effects than CQ because of its lower level of 
tissue accumulation [63]. In contrast to HCQ, CQ 
is considered unsafe to be given during pregnan-
cy due to its teratogenic effect on the fetus. This 
supports using HCQ rather than CQ in treating 
pregnant women with SARS-CoV infection. HCQ 
can cause QT interval prolongation leading to 
torsade de pointes in some individuals. Despite 
being rare, this side effect can by amplified by 
using other drugs such as azithromycin that has 
been suggested to be used in combination with 
HCQ [62].
Lopinavir/ritonavir combination
The HIV antiretroviral combination lopina-
vir/ritonavir that is called Kaletra or Aluvia [64] as 
been used to treat patients with COVID-19. Lopina-
vir and ritonavir are protease inhibitors that have 
shown some activity against SARS-CoV-2 in vitro, 
however currently, there is no strong evidence of 
benefit to use it against COVID-19 [65]. Lopina-
vir inhibits the activity of 3-chymotrypsin-like 
protease (3CL) which has a role in viral RNA 
processing. Ritonavir inhibits the metabolizing 
enzyme cytochrome P450 3A and that increases 
the half-life of lopinavir, subsequently, affecting 
viral replication and release from host cells [66]. 
Previous studies investigating the activity of 
lopinavir/ritonavir against SARS and MERS were 
limited, still they showed a decrease in incubation 
period and mortality rate [67]. Up till now there 
has been no published data for this combination 
supporting its use for SARS-CoV-2. Cao et al. in-
vestigated the efficacy of Kaletra through conduct-
ing a randomized, controlled, open-label study. 
A total of 199 patients were included, 99 subjects 
were allocated to the lopinavir/ritonavir group, 
and the rest (100 patients) to the supportive care 
group [67]. The results, unfortunately, were not 
promising, and there were no benefits observed 
with lopinavir/ritonavir therapy over supportive 
care. In a different study from China, the authors 
have investigated the risk factors for prolonged 
SARS-CoV-2 shedding among 120 patients con-
firmed to have COVID-19 using tRT-PCR. They 
have reported a shorter median duration of viral 
shedding with early administration, within the 
first 10 days from the symptoms onset, of lopina-
vir/ritonavir treatment by 6.5 days [64]. However, 
reported serious adverse effects such as induced 
transaminase elevation and hepatotoxicity, limit 
this therapy in treating patients with COVID-19, 
especially those with liver injury [68]. At present, 
there is a lack of evidence to recommend the use 
of this combination for treatment of COVID-19, 
and more RCTs are required to assess the efficacy 
and safety of this therapy.
Ivermectin
Ivermectin is an FDA-approved anti-parasit-
ic drug which has shown an antiviral effect on 
human immunodeficiency virus (HIV) [69]. It 
is known to inhibit the interaction of integrase 
protein (IN) of HIV-1 and the importin (IMP) 
α/b1 heterodimer that is important for IN nucle-
ar transportation of viral proteins [70]. As this 
process is important for viral replication cycle, 
affecting the nuclear import can be considered 
as a therapeutic approach against RNA virus-
es. Recently, a group of Australian researchers 
have shown an in vivo activity with capability 
of ivermectin to significantly reduce the virus 
replication within two days [70]. Further research 
is required to evaluate ivermectin`s efficacy on 
treating SARS-CoV-2 infections.
Remdesivir
Remdesivir, which is known as GS-5743, 
has a broad-spectrum antiviral activity against 
RNA viruses such as filoviruses, pneumoviridae 
and paramyxoviruses [71], it has shown an in 
vitro activity against reported cases infected with 
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SARS-CoV-2 [72]. Remdesivir is intracellulary 
metabolized to adenosine triphosphate analogue 
that blocks viral replication by inhibiting the viral 
RNA polymerases [73]. Initial animal experiments 
showed some activity against Ebola virus, how-
ever, a recent randomized controlled trial in the 
Democratic Republic of the Congo (DRC) showed 
that remdesivir was less effective in reducing 
mortality compared to single and triple mono-
clonal antibody-based treatments. However, this 
trial has proven the safety of its use in humans, 
which led the researcher to consider using it in 
COVID-19 clinical trials [74]. Recently, William-
son et al. have shown that remdesivir treatment 
was effective in reducing lung damage and disease 
progression in infected rhesus macaques monkeys 
with SARS-CoV-2 [75]. Moreover, Grein et al. have 
published their experience with compassionate 
remdesivir treatment in 53 patients with severe 
COVID-19, as a 10-day course of remdesivir at 
a dose of 100 mg intravenously proceeded by 
a loading dose of 200 mg used and followed up 
for 28 days. A clinical improvement in terms of 
respiratory support was observed in 36 (68%) pa-
tients [76]. Remdesivir is currently being tested in 
clinical trials in different countries, two of these 
trials are randomized phase 3 trials in China.
Favipiravir
Similar to remdesivir, favipiravir inhibits the 
RNA polymerase activity affecting viral replica-
tion [77]. Favipiravir (FPV) is one of the medica-
tions approved for treating influenza. However, 
there has not been strong evidence to support its 
use to treat patients with COVID-19 compared to 
remdesivir [77]. Nevertheless, Cai et al. evaluated 
the effects of favipiravir against lopinavir/ritona-
vir for treatment of SARS-CoV-2. An oral favip-
iravir was used in a combination with an inhaled 
interferon-α for the synergistic effect of viral 
inhibition. Their results were promising as the 
patients in the FPV arm showed better clinical 
response in terms of viral clearance and disease 
progression with minimal adverse effects [78]. 
Consequently, in March 2020, the National Med-
ical Products Administration of China approved 
FPV as the first drug to treat COVID-19. 
Ribavirin
Ribavirin is a guanosine analog that affects 
the replication of RNA and DNA viruses. It also 
inhibits the production of guanosine from the 
guanine precursor by influencing the function 
of inosine monophosphate dehydrogenase which 
further affects virus stabilization [79]. Early ad-
ministration of ribavirin has been reported to be 
beneficial in treating COVID-19-related pneumo-
nia [80]. Ribavirin has been used in combination 
with the protease inhibitor lopinavir/ritonavir 
given the previously proven efficacy against 
SARS. Chu et al. examined the clinical response 
of 41 COVID-19 patients who were followed up 
to 3 weeks to a combination of lopinavir/ritonavir 
and ribavirin, compared to 111 controls who were 
SARS infected patients and received only ribavi-
rin. The study subjects in the lopinavir/ritonavir 
and ribavirin treatment group had lower adverse 
clinical outcomes represented by ARDS or death 
compared to the control group. In addition, 
a reduction in both steroid use and nosocomial 
infections were noticed as well [81].
Systemic glucocorticoids
Given the high levels of cytokines that are 
induced by COVID-19, corticosteroids have been 
used for their anti-inflammatory effect to treat 
critically ill patients. However, current research 
suggested no reduction in mortality rate, but 
delayed viral clearance and high viral load [82, 
83]. However, there is an argument for using 
systemic corticosteroids in patients who develop 
ARDS as a complications of COVID-19 infection, 
where in this setup it seems that they decrease the 
duration of mechanical ventilation and hospital 
mortality [84].
Corticosteroids were widely used during 
SARS-CoV outbreak due to their ability to mod-
ulate the inflammatory response [85]. At present, 
there is no clear evidence for or against cortico-
steroid use in the treatment of SARS-CoV-2 pa-
tients. There is some proof that corticosteroid use 
during early phase of infection may be beneficial 
[85]. However, corticosteroid should be applied 
carefully until further evidence that is specific to 
SARS-CoV-2 infection emerges. 
Intravenous immunoglobulin 
(convalescent plasma therapy)
Immunocompromised patients and individ-
uals with immunological disorders appear to be 
at higher risk of developing serious complica-
tions related to COVID-19 disease compared to 
healthy individuals. Immunotherapy using im-
munoglobulin G (IgG) could be used in combina-
tion with antiviral agents to treat COVID-19 and 
to strengthen patients’ immune response against 
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SARS-CoV-2 [86]. Hofmann et al. reported that 
sera from healthy individuals contain anti-coro-
navirus antibodies [87]. In addition, Pyrc et al. 
in a study on HCoV-NL63, showed that the in-
fection caused by HCoV-NL63 can be inhibited 
by human sera from healthy adults [88]. Boukh-
valova et al. reported an improved outcome of 
RSV infections among immunocompromised pa-
tients who were treated with IV Ig obtained from 
previously infected donors who had a high-titer 
antibodies against RSV [89]. Thus, immunother-
apy using immune IgG antibodies collected from 
adults recovered from SARS-CoV-2 infection 
could be a promising modality of treatment for 
patients with COVID-19. It has been reported 
that immune IgG antibodies are more efficient 
in terms of virus neutralization, if collected from 
patients who live in the same city because of the 
effect of lifestyle and environmental factors on 
specific antibodies development against virus-
es [86]. Using immune IgG antibodies against 
SARS-CoV-2 infection can help newly infected 
patients by boosting their immune response to 
the infection. Thus, a combination of antiviral 
drugs and immunotherapy can be used as an 
alternative treatment for COVID-19 until a vac-
cine is developed.
Interleukin (IL)-6 pathway inhibitors
IL-6 is one of the key cytokines produced 
by activated macrophages. In their systematic 
review, Coomes et al. demonstrated significantly 
higher serum levels of IL-6 in patients requiring 
ICU admissions than non-ICU patients, suggest-
ing that serious complications of COVID-19 can 
be related to a host immune response and au-
toimmune damage [90]. Furthermore, Zhou et 
al. reported a correlation between the serum 
levels of IL-6 and the mortality in patients with 
COVID-19 [91]. IL-6 is important for produc-
tion of T helper 17 (Th17) cells. Excessively 
activated Th17 cells reported in patients with 
COVID-19 can be explained by the high levels 
of IL-6 [92]. Elevated levels of IL-6 negatively 
impact the lung elasticity and are associated with 
severe bronchoalveolar inflammation [13]. Thus, 
using agents that inhibit the cytokine pathway 
at the level of IL-6, such as tocilizumab can be 
beneficial in managing inflammatory response 
squeals. Tocilizumab (TCZM) is a recombinant 
monoclonal antibody that binds to both soluble 
and membrane-bound receptors [93]. Tocilizumab 
is not approved for COVID-19 treatment. Howev-
er, clinicians are using it under emergency use 
authorization [93]. There is limited high-quality 
published evidence for IL-6 inhibitor use against 
COVID-19 [94]. However, a very recent systematic 
analysis that included sixteen case-controlled and 
eighteen uncontrolled studies revealed positive 
evidence for the potential efficacy of TCZM to 
treat severe cases of COVID-19 [93]. The World 
Health Organization (WHO) recommends the 
use of IL-6 inhibitors only in clinical trials. But, 
many organizations have included IL-6 inhibitors 
as an option for treating COVID-19 patients with 
severe disease [94]. Other IL-6 inhibitors such as 
sarilumab and siltuximab have been evaluated for 
the management of COVID-19 patients, with no 
strong evidence to be used in the management of 
COVID-19 patients [94].
Amantadine
Amantadine is a drug used to treat Par-
kinson’s disease. It could be used to mitigate 
COVID-19 effects; the researches have shown 
that patients with Parkinson’s disease who are 
treated with amantadine and have been infected 
with SARS-CoV-2 virus have been asymptomatic 
[95]. Its proposed mechanism of action is that 
it blocks the early stages of viral replication. 
Moreover, it is hypothesized that amantadine 
prevents the release of the viral nucleus into 
the cell cytoplasm by blocking the viroporine 
channel of SARS-CoV-2 [96]. Very recently, 
Jiménez-Jiménez et al. studied the anti-inflam-
matory effects of amantadine and its therapeu-
tic influence in treating COVID-19. They have 
suggested two pharmacological effects: antivi-
ral and anti-inflammatory [97]. Furthermore, 
Abreu et al. have proposed that early use of 
amantadine could mitigate COVID-19 disease 
consequences [96]. Further randomized clinical 
trials are required to prove its usefulness in 
COVID-19 management. 
Systemic anticoagulation
Researchers in several centers caring for 
adult patients with severe COVID-19 disease 
noted an increased incidence of thromboem-
bolic events. Those patients typically required 
ICU admission and mechanical ventilation. Two 
studies looked at the use of systemic anticoag-
ulation and the impact on in-hospital mortality 
and reported improved outcomes [98, 99]. In an 
updated recommendation, the NIH in the US 
added the use of systemic anticoagulants in its 
recommendations for the care of hospitalized 
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critically ill adult patients with COVID-19 [100]. 
One of the anti-coagulant agents that were tried 
on COVID-19 patients is sulodexide. It is a natu-
ral glycosaminoglycan composed of fast-moving 
heparin (80%) and dermatan sulfate (20%) [101]. 
It has an arterial and venous anti-thrombotic 
action and ani-inflammatory activity through 
suppression of IL-6 production [101]. Compared 
with low-molecular-weight heparin (LMWTs), 
sulodexide is associated with less bleeding risk 
and is safe to be given to patients with renal 
insufficiency [102]. This drug may represent an 
alternative prophylactic agent to LMWH [102]. It 
was hypothesized that the early use of sulodexide 
in COVID-19 patients with comorbidities might 
reduce the severity of the disease and prevent the 
development of severe complications [103]. Bik-
deli et al. reviewed 6 randomized controlled trials 
(RCTs) where the use of sulodexide was compared 
with placebo. The sulodexide administration was 
associated with a reduction in the odds ratio of 
cardiovascular mortality, deep vein thrombosis, 
and myocardial infarction [104]. However, addi-
tional RCTs with this drug are warranted. 
Respiratory support
Hypoxemia is common in hospitalized 
COVID-19 patients. More than a quarter of the 
hospitalized COVID-19 subjects require inten-
sive care due to acute respiratory failure [105]. 
Conventional oxygen therapy can be insufficient 
to meet oxygen needs of individuals with acute 
hypoxic respiratory failure [106]. Options for 
treating hypoxic patients, other than conventional 
oxygen therapy, include high-flow nasal cannula 
(HFNC), noninvasive positive-pressure ventila-
tion (NIPPV), or intubation and invasive mechan-
ical ventilation. Based on meta-analysis and data 
from non-COVID-19 clinical trials that showed 
reductions in the need for intubation in patients 
who received HFNC or NIPPV, these options are 
preferable to conventional oxygen therapy [107]. 
Furthermore, HFNC use is preferred over NIPPV 
in hypoxic patients due to acute respiratory 
failure [108]. Patients with COVID-19 should be 
monitored for signs of respiratory deterioration. 
Early intubation should be considered when the 
patients’ condition deteriorates and they have ad-
ditional acute system dysfunction or when HFNC 
and NIPPV are not available to treat the hypoxic 
acute respiratory failure [106]. If required, intu-
bation should be performed by experienced staff 
in a controlled setting to ensure the safety of both 
patients and healthcare workers. 
Use of antibiotic therapy
A meta-analysis of small case series reported 
that 3.5% of COVID-19 patients had a bacterial 
co-infection, and 14% had a secondary bacterial 
infection [109]. Superimposed bacterial infections 
have been reported in 28% of severely infected and 
critically ill COVID-19 patients, which may sup-
port the antibiotic use in intensive care units [110]. 
Despite the lack of reported cases of initial super-
infections, there is widespread use of antibiotics 
in hospitalized COVID-19 patients. Antibiotic use 
in patients with COVID-19 has not been shown to 
affect clinical outcomes. Contrary, unnecessary an-
tibiotic use has been associated with an increased 
risk of resistant hospital-acquired bacterial and 
fungal infections [111]. Antibiotic therapy is not 
recommended for COVID-19-related pneumonia 
unless a secondary bacterial infection is suspected. 
Vaccine development
Since the full genomic sequence of SARS- 
-CoV-2; the cause of the novel coronavirus pan-
demic (COVID-19) has been published [112], 
many countries, institutions, and pharmaceutical 
companies started racing to develop an effective 
and safe vaccine, as it’s the most reliable and 
cost-effective method to control any emerging 
viral infection and flatten its transmission curve 
as well as to prevent any re-emergences of the 
disease in the future. According to the WHO, 
until this date, more than 40 programs are work-
ing on a vaccine against SARS-CoV-2 [113], only 
two of them entered the clinical trials; recom-
binant adenovirus vector vaccine which is in 
phase-2 clinical trial [114], and mRNA-based 
vaccine in phase-1 [115].
In addition to live vector and RNA-based 
vaccines, candidates using other platforms, such 
as the whole virus; either killed or live attenuated 
[116–118], DNA-based [119, 120], and recombi-
nant subunit vaccines, are also under develop-
ment ; which is currently getting a lot of attention 
since the surface S glycoprotein has shown to 
be the main target for subunit vaccines against 
MERS-COV and SARS-COV [121–124], and it is 
expected to be the same for SARS-CoV-2 due to 
the reported high genetic similarities especial-
ly with SARS-COV [126, 127]. Several studies 
have shown that S glycoprotein and its RBD 
fragment is an ideal vaccine target against SAR-
CoV-2 [127–132]. To date all S glycoprotein-based 
vaccine candidates targeting SARS-CoV-2 are still 
in preclinical phase [113]. Another interesting 
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subunit vaccine targets are specific B and T cell 
epitopes [133–135]. However, as vaccines usually 
take at least one year to be available, alternative 
options should be considered.
Existing and widely used vaccines may 
serve a potential protective effect against SARS-
CoV-2 as it has been observed that the incidence 
of COVID-19 in groups who are vaccinated rou-
tinely, especially children, is very low [136, 137], 
and recently, it has been hypothesized that BCG 
vaccine may offer a protective shield against 
COVID-19 based on observations that compared 
the prevalence of COVID-19 in countries where 
BCG is a national program with other countries 
[138, 139].  However, two clinical trials have 
been started to assess its efficacy in protecting 
healthcare workers who are in contact with 
COVID-19 patients [140, 141]. Another interest-
ing short-term protection alternative option is 
convalescent sera which provide an immediate 
passive immunity by administering the collected 
antibodies from recovered patients in susceptible 
individuals [142, 143], thus, convalescent plasma 
combined with other potential therapeutic drugs 
may serve a good alternative treatment until 
strong options such as vaccines are available. As 
for any vaccine, in addition to the time it takes 
to be developed and evaluated, it also poses 
some challenges regarding its candidate such as 
antibody-dependent enhancement (ADE); a phe-
nomenon in which the viral antigens used by 
the vaccine may induce the same disease they’re 
supposed to protect from [144]. Moreover, RNA 
viruses; which are the big family of coronaviruses 
have been shown to have a higher rate of mu-
tations when they’re compared to DNA viruses 
[145, 146].
In the past, vaccines were developed through 
many steps that might have taken several 
years. Recently, given the urgent need to devel-
op a COVID-19 vaccine, some of the vaccine de-
velopment steps are happening in parallel while 
maintaining safety standards. For example, mul-
tiple vaccines are evaluated at the same time by 
some clinical trials [147]. Clinical development 
of a new vaccine is a three-phase process. During 
phase-1, small groups of healthy adult volun-
teers should be enrolled. In phase-2, the vaccine 
is given to groups of volunteers that reflect the 
populations for whom the vaccine is intended. In 
phase-3, the vaccine is given to large groups of 
people (thousands) to test its efficacy and safety 
[148]. Multiple vaccines are being tested in ear-
ly-phase studies, and some vaccine participants 
are in phase-3 studies assessing efficacy [149]. 
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